Skip to main content
Premium Trial:

Request an Annual Quote

Kapa Biosystems to Supply Reagents for 10X GemCode Platform

NEW YORK (GenomeWeb) – Kapa Biosystems will supply DNA library prep reagents for 10X Genomics' GemCode platform, the companies said today.

GemCode is a molecular barcoding and analysis platform that consists of instrumentation, reagents, and software to generate a data type called Linked-Reads, which deliver long-range information, including haplotype phasing, structural variation, and other critical genomic information from as little as 1 nanogram of DNA.

Kapa uses a proprietary directed evolution technology platform to engineer enzymes for the specific performance and functional requirements of next-generation sequencing sample prep. The GemCode Platform incorporates both the KAPA Hyper Prep Kit and KAPA HiFi DNA Polymerase in the library construction process to enable high-efficiency adapter ligation and low-bias library amplification, the companies said.

Financial and other terms of the agreement were not disclosed.

10X Genomics previewed GemCode at the Advances in Genome Biology and Technology meeting in late April, and began shipping the platform earlier this month.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.